Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDavid CunninghamUFUmar FarooqTFTatyana Feldman

Discussion

Loading...

Member takes

Overview

Pivotal trial reports sustained complete response in patients with relapsed large B-cell lymphoma, highlighting potential long-term survival benefits of epcoritamab.

Key Points

  • Forty-two percent of complete responders remained in remission after over four years of treatment.
  • Complete response rates were documented at 41% among patients undergoing epcoritamab therapy.
  • Observation of the overall survival rate revealed a median of 18.5 months for patients treated with epcoritamab.
  • Improved safety profile indicates epcoritamab as a favorable chemotherapy-free option for difficult large B-cell lymphoma cases.

Cite This Study

Cunningham et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d515https://doi.org/10.1182/blood-2025-5513
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response2025
  2. 2Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial2025 · 4 citations
  3. 3Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 1 citations
  4. 4Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  5. 5Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial2025